bioRxiv Science⌕ Search

bioRxiv · 10.64898/2025.12.07.692834

zifalsnm: Zero-Inflated Bayesian factor analysis model with skew-normal priors for modeling microbiome data

Abstract

BackgroundAdvancements in next-generation sequencing have transformed our understanding of host-microbe interactions, revealing links between microbial composition and chronic conditions such as diabetes, Crohns disease, and others. However, the analysis of microbiome data is complex due to its high-dimension as well as additional statistical characteristics. One primary objective is to achieve effective dimensionality reduction while simultaneously accounting for the datas compositional nature and zero inflation. Existing probabilistic models are often based on the assumption that the log-ratio-transformed compositions are normally distributed. This assumption is problematic because it can fail to capture the significant skewness inherent in these transformed compositions. ResultsWe propose a new model called the Zero-Inflated Factor Analysis Logistic Skew-Normal Multinomial (ZIFA-LSNM) model. ZIFA-LSNM integrates a zero-inflation component to handle excess zeros, employs factor analysis for dimensionality reduction, and, critically, utilizes skew-normal priors on the latent factors to explicitly model data asymmetry. Posterior inference is performed using an efficient variational inference algorithm. Through simulation studies and real data analysis, the ZIFA-LSNM model is shown to have improved performance in parameter recovery and composition estimation compared to its Gaussian-based counterparts. ConclusionThe ZIFA-LSNM model demonstrates that explicitly accounting for skewness in the latent factor structure can substantially improve inference in commonly-observed microbiome data. The proposed model, therefore, offers a flexible and scalable framework allowing for the improved analysis of the complex relationships between microbial communities and human health.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Panchasara, S., Jankowski, H., McGregor, K.. 2025-12-10. zifalsnm: Zero-Inflated Bayesian factor analysis model with skew-normal priors for modeling microbiome data. https://doi.org/10.64898/2025.12.07.692834

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗